
Epilep200 mg
Beximco Pharmaceuticals Ltd.
Carbamazepine is an anticonvulsant and mood-stabilizing agent with established uses across several conditions and more.
Carbamazepine is an anticonvulsant and mood-stabilizing agent with established uses across several conditions, supported by different levels of clinical evidence:
Use of Carbamazepine for any indication should be individualized and supervised by a physician.
| Population | Initial Dose | Titration | Usual Maintenance / Maximum |
|---|---|---|---|
| Adults and children >12 years | 200 mg twice daily | Increase by up to 200 mg/day at weekly intervals, divided doses | Usual maintenance 800–1200 mg/day; maximum generally 1000 mg/day (12–15 years) to 1200 mg/day (>15 years), occasionally up to 1600–2000 mg/day under specialist supervision |
| Children 6–12 years | 100 mg twice daily | Increase by up to 100 mg/day at weekly intervals, divided doses | Maximum 1000 mg/day |
| Children under 6 years | 10–20 mg/kg/day in 2–3 divided doses | Increase gradually as needed and tolerated | Individualized; per specialist guidance |
Initial: 100 mg twice daily on day 1, increased gradually by up to 200 mg/day as needed for pain relief. Usual maintenance dose is 400–800 mg/day; maximum 1200 mg/day. Attempts to reduce to the minimum effective dose should be made at intervals of 3 months.
Extended-release formulation: initial 200 mg twice daily, adjusted in increments of up to 200 mg/day; usual target dose range 400–1600 mg/day in divided doses, guided by clinical response and tolerability.
Take with food to minimize gastrointestinal upset. Extended-release tablets/capsules must be swallowed whole and not crushed or chewed. Chewable tablets should be chewed thoroughly. Shake oral suspension well before use. Do not switch abruptly between formulations without medical guidance, as bioavailability differs.
Use with caution in hepatic impairment; dose reduction or avoidance may be needed in significant hepatic disease. No formal dosage adjustment is established for renal impairment, but caution is advised, and levels should be monitored.
Serious warnings (see Precautions and Warnings for full detail): severe dermatologic reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) and blood dyscrasias (aplastic anemia, agranulocytosis).
Carbamazepine is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.